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In addition to well-characterized CD34+ hematopoi-
etic stem and progenitor cells (HSPCs), the human
hematopoietic stem cell (HSC) hierarchy contains a
rare CD34 population with severe combined immu-
nodeficiency-repopulating capacity. However, little
is known about the molecular characteristics of
these CD34 cells or their relationship to the CD34+
populations. Here, we show that the self-renewing
LinCD34CD38CD93hi population contains cells
that not only function as HSCs, but can also be
placed above the CD34+ populations in the hemato-
poietic hierarchy. These cells have an active Notch
pathway, in which signaling through Delta4 is crucial
for maintenance of the primitive state, and combined
signals from Jagged1 and TGF-b are important in
controlling its quiescence. They are also refractory
to proliferative signals and show a repressed canon-
ical Wnt pathway, in part regulated by Notch. Overall,
therefore, CD34 cells represent an immature and
quiescent human HSC population maintained
through a distinctive network of cellular signaling
interactions.
INTRODUCTION
Although most human stem cell and progenitor activity is asso-
ciated with CD34 expression, the existence of primitive hemato-
poietic cells in humans and rhesus monkeys that are negative for
CD34 expression has been described (Goodell et al., 1997).
Furthermore, a rare population of human cells devoid of CD34
expression with severe combined immunodeficiency (SCID)-
repopulating cell (SRC) activity has also be identified (also
defined as LinCD34CD38, or simply denoted as/) (Bhatia
et al., 1998). It has additionally been reported that CD34 expres-
sion can be induced on these cells in vitro by hematopoietic
cytokines (Nakamura et al., 1999); however, such cells have a
weaker SCID-repopulating activity compared to primary, unma-Cnipulated CD34+ hematopoietic stem and progenitor cells (HSCs
and HPCs, also called HSPCs) (Nakamura et al., 1999). This im-
plies that the induction of CD34 expression from primary /
cells does not produce true CD34+ SRCs, because CD34
expression on human HSPCs can be downregulated, both
in vitro and in vivo, without compromising repopulating capacity
(Dao et al., 2003; Kuc¸i et al., 2003). Therefore, it has been thought
that the acquisition of CD34 expression on primary / cells
could be merely an upregulation of this antigen and not a devel-
opmental differentiation toward a CD34+-SRC type.
We have previously shown that only the CD93hi (mouse homo-
log of AA4.1 or C1qRp) subfraction within the LinCD34CD38
cell population has SCID-repopulating capacity (Danet et al.,
2002). Our understanding of the biology of primary
LinCD34CD38CD93hi cells and the contribution of this rare
population to the maintenance of human hematopoiesis remains
limited. The unique cellular and molecular features that distin-
guish these cells from CD34+ HSPCs, as well as the signaling
pathways that regulate their properties, have yet to be eluci-
dated. Here, we report that this rare population has the ability
to self-renew and is more primitive than the LinCD34+CD38
(+/) cell population, because it is able to generate self-
renewing +/ cells in vivo and is more competent in serial trans-
plants than the +/ cell population. We further demonstrate that
the combination of Notch, transforming growth factor b (TGF-b),
and (repressive) canonical Wnt pathways plays a central role in
their unique biology.RESULTS
Lin–CD34–CD38–CD93hi Population Resides at the Top
of the Human HSPC Hierarchy
It has previously been reported that human CD34+ cells can be
generated from cord blood (CB) LinCD34 in immunodeficient
mice, and that these CD34+ cells are capable of producing sec-
ondary grafts (Wang et al., 2003). To further elucidate the in vivo
relationship between the/ and +/ populations, we began by
purifying (>99% purity) the two populations from CB and trans-
planted them into primary nonobese diabetic (NOD)/SCID-
b2/ recipient mice using an equivalent number of SRCs
(1.2 SRCs/mouse; Figure S1A available online). At 3 weeksell Stem Cell 13, 161–174, August 1, 2013 ª2013 The Authors 161
Figure 1. In Vivo Self-Renewal Capacity of Different CB Populations
(A) Approximately 1.2 LinCD34CD38 (/; 75,000 cells) and LinCD34+CD38 (+/; 750 cells) SRCs were intravenously (i.v.) injected into separate primary
NOD/SCID-b2/ recipients, and at different weeks after transplant mice were sacrificed and human graft was determined. Calculation of the SRC frequency for
each population can be seen in Figure S1. w, weeks.
(B) Approximately 5,000 //+ and 750 +/ cells were i.v. injected into primary NSG recipients, and human graft was determined at 12 and 24–26 weeks after
transplant. BMs were sampled at 12 weeks for determining human chimerism in mice. eq., equivalent.
(C) Secondary transplant with LinCD34CD38\lo (312,500, B25,000, 640,000, ,60,000, >90,000) and LinCD34+CD38\lo (A1,250, C2,400, :4,800,
-10,000) cells that were FACS-sorted from primary recipients’ BM originally transplanted with CB / (left) or +/ (right) cells.
(D) Ex vivo replating potential of engrafted LinCD34+CD38\lo (+/\lo) cells isolated from primary NSG mice transplanted with CB //+ or +/ cells at
24–26 weeks posttransplant (n = 6).
(E) Frequency of +/\lo populations found in the primary mouse BM at different time points and in the different mouse strains shown in (A) and (B).
(F) qRT-PCR for the expression of p16INK4A and p21CIP1 in the +/\lo populations used for secondary transplant (C) and ex vivo replating assays (D), respectively
(n = 5–7). ND, not detected.
Median bars are shown; *p% 0.03, **p% 0.003. See also Figure S1.
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lymphoid engraftment, whereas such engraftment from /
cells was not seen until 6 to 9 weeks (Figure 1A). Although this
myelo-lympoid engraftment was undetectable at 3 weeks in
the / population, the cells did localize in the mouse bone
marrow (BM), remaining undifferentiated and quiescent (Fig-
ure S1B) at early time points, suggesting that they had success-
fully homed. Notably, most of these homed/ cells expressed
CD93 (Figure S1B), confirming our previous finding that only the
subfraction of / cells expressing the complement receptor
CD93 show SRC activity (Danet et al., 2002). In CB, the
LinCD34CD38CD93 population was almost all CD7+ (and
also CD45RA+; Figure S2A), and therefore probably represents
natural killer progenitors (Storms et al., 2000). As such, for
achieving a more purified population, the CD34CD38
CD93hi(CD7/CD45RA)  (//+) population was used in subse-
quent experiments.
We repeated the primary transplantation experiments
using //+ and +/ populations and transplanted them into
separate IL2Rgnull NOD/SCID (NSG) mice. Although we
observed that //+ cells yielded a >50-fold-lower engraftment162 Cell Stem Cell 13, 161–174, August 1, 2013 ª2013 The Authorsthan +/ cells at 12 weeks, the engraftment level produced
by //+ cells eventually matched or surpassed the levels pro-
duced by +/ cells at 24–26 weeks (Figure 1B).
For addressing the self-renewal capacity of primary /
cells, BM from each group of NOD/SCID-b2/mice was recov-
ered at 12 weeks posttransplant and pooled, and human cells
were again sorted via fluorescence-activated cell sorting
(FACS) for populations phenotypically similar to the initial popu-
lations, CD45+LinCD34CD38\lo (/\lo) and CD45+
LinCD34+CD38\lo (+/\lo), then transplanted into secondary
recipients.
Both/\lo and +/\lo populations derived from primary/
grafts were able to engraft (Figure 1C); however, cells derived
from primary +/ transplants only showed engraftment in
the +/\lo compartment (Figure 1C). Furthermore, +/\lo cells
derived from the primary / population were more efficient at
engrafting secondary recipient mice as compared to those
derived from primary +/ grafts, in that at least an 2-fold lower
number of +/\lo cells were required for engraftment (1,250 cells
derived from / versus 2,400 or more cells derived from +/;
Figure 1C). Also, the /\lo population derived from the
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a phenotype corresponding to the original CB fraction previously
shown to have SRC activity, whereas a similar subpopulation
derived from +/ HSPCs was not present (Figure S1C) (Danet
et al., 2002). As a result, /\lo cells derived from CB +/
HSPCs, despite containing CD93+ cells, failed to engraft even
at doses 7-fold higher as compared to those derived from
CB / cells (Figure 1C). Further phenotypic analysis demon-
strated that these cells represent macrophages (CD117HLA-
DR+CD11b+; Figure S1C).
Furthermore, +/\lo cells recovered from NSG mice trans-
planted with CB //+ cells have better ex vivo replating
capacity as compared to the similar population derived from
CB +/ cells (Figure 1D). A higher frequency of +/\lo cells
was generated from the CB / and //+ cells compared to
the +/ population in both animal models used (Figure 1E). Addi-
tionally, higher expression of CDKN2A (p16INK4a) and CDKN1A
(p21CIP1) transcripts were found in +/\lo cells derived from
CB +/ HSPCs than CB / or //+ cells, suggesting cell-
cycle arrest and signs of exhaustion (Figure 1F).
Lin–CD34–CD38–CD93hi HSCs Are Quiescent and
Immature
Given their ability to generate +/ cells, self-renew, and pro-
duce long-term engraftment with fewer signs of exhaustion,
we were interested in whether the //+ cells are a more
quiescent and primitive population as compared to the +/
population, with respect in particular to the four +/ subfrac-
tions that have been recently described based on the expres-
sion of CD45RA, CD90, and CD49f (CD45RACD90+or
CD49f+or, referred to herein as 90+or49f+or) (Notta et al.,
2011). To delineate the developmental relationship between
the //+ and +/ compartments, we performed a comparison
with the aim of finding a +/ subpopulation closely related to
the //+ cells. We also attempted to further dissect
the //+ fraction using the same antigens. However, we
found that //+ cells are CD45RA, CD90 (Danet et al.,
2002), and CD49f (Figure S2A). These cells are also
CD133Tie2 (Figure S2B), and as such, we could not further
divide the //+ population using recently published surface
antigens important for subfraction +/ cells.
To assess their relative states of quiescence, we performed
cell-cycle analysis and found that the //+ cells are largely
Ki67 negative compared to the +/ population and all of its sub-
populations that are Ki67 low (Figure 2A), indicating that
the //+ population is highly quiescent. We confirmed that
the //+ population express higher levels of cell-cycle regula-
tors responsible for maintaining the cells in G0 state than any of
the +/ subfractions, such as E2F4, RBL2 (p130), CDKN1B
(p27KIP1), and p21CIP1 (Figure 2B). We further confirmed the in-
crease of Rbl2 at the protein level (Figure 2C).
In addition to cell-cycle regulators, there are transcription fac-
tors that are known to be important for the development, activity,
and proliferation of HSCs, which could be differentially ex-
pressed, as compared to +/ HSPCs (referred to here as
‘‘HSC fingerprint’’ transcription factors). Given that the //+
population has little to no clonogenic activity in vitro (Danet
et al., 2002) and displays a delayed engraftment kinetic in vivo,
we compared the expression of these HSC fingerprint transcrip-Ction factors between the//+ and the +/ subpopulations. We
observed that//+ cells express lower levels ofGATA2, LMO2,
TAL1, RUNX1A, and MYB (Figure 2D) compared to all the +/
fractions described here. The lower expression of these factors
was again confirmed at the protein level for Lmo2 and Scl/Tal1
(Figure 2E). Taken together, LinCD34CD38CD93hi is the
most quiescent population of cells with HSC activity and prob-
ably represents a very immature population.
Active Notch Signaling in Lin–CD34–CD38–CD93hi HSCs
Given the differences we observed between the populations with
respect to cell cycle and the expression of HSC fingerprint tran-
scription factors, we wanted to determine which signaling path-
ways regulate the quiescent state and immaturity of the //+
population. We first looked at the Notch pathway, because it
has been shown to regulate differentiation and cell-cycle pro-
gression in human HSPCs (Delaney et al., 2005; Lauret et al.,
2004).
We found that Notch3 expression was absent, but//+ cells
express Notch1 and Notch2, as well as high levels of Notch4,
compared to the +/ fractions (data not shown and Figure 3A).
Additionally, //+ cells express the components of the Notch
pathway, in particular DTX1 (DELTEX1, a potential negative
regulator when high Notch activity is present), and the down-
stream target genes at a higher level compared to the other
cell populations (Figure 3B). Hes1 protein was also found to be
highly expressed in the //+ population (Figure 3C). Addition-
ally, we looked at the cleaved forms of Notch, which are indica-
tive of Notch activity. The //+ cells have very low levels of
cleaved Notch1 but express the cleaved Notch2 (Figure 3D)
and, perhaps most importantly, show nuclear expression of the
intracellular form of Notch4 (N4-IC; 30% nuclear localization;
Figure 3D). Considering the fast turnover of this pathway (Fryer
et al., 2004; Ilagan et al., 2011), this indicates that //+ cells
have significant Notch4 receptor processing. Moreover, this
expression pattern appears to be unique to the //+ popula-
tion; we found that +/ HSPCs have a different pattern of Notch
receptor cleavage (Figure 3D).
In order to see whether CB HSPCs are likely to receive Notch
signals from their natural environment, we performed immuno-
histochemistry on tissue from the placental villi and umbilical
cords (Figure 3E), where CB HSPCs would normally reside,
especially the placenta villi, which represents a large surface
area. We observed that the placenta villi and umbilical cord ar-
teries and vein express Jagged1 (Jag1) and high levels of Delta4
(Dll4) (Figure 3E) but Delta1 could not be detected (Dll1;
Figure S3A).
Notch Signaling Is Important in the Maintenance of the
Distinctive Features of Lin–CD34–CD38–CD93hi HSCs
Because the//+ population has an active Notch pathway, we
were interested in whether it played a significant role in themain-
tenance of these cells. As we are not yet able to maintain //+
cells in vitro without a supportive feeder layer for more than a few
days before they become apoptotic, we were not able to silence
the components of the pathway by using a small hairpin RNA-
lentivirus approach to investigate its role. Instead, we cultured
the cells on the stromal cell line, S17, which maintains
the //+ cells and promotes their differentiation. Importantly,ell Stem Cell 13, 161–174, August 1, 2013 ª2013 The Authors 163
Figure 2. Lin–CD34–CD38–CD93hi HSCs Are Quiescent and Immature
(A) Cell-cycle profile of the different CB HSPC populations: //+, +/, and the four different LinCD34+CD38CD45RACD90+orCD49f+or populations (see
Figure S2) determined by Ki67 and DAPI staining (n = 5).
(B) qRT-PCR for different cell cycle regulators genes. Expression values were normalized to //+ as reference population (n = 3-5).
(C) Immunocytochemistry of Rbl2 (p130) staining in the indicated CB HSPC populations (scale bars represent 5 mm).
(D) Expression of different ‘‘HSC fingerprint’’ genes. //+ cells were used as a reference population (n = 3–5).
(E) Immunocytochemistry of Lmo2 and Scl/Tal1 in different CB HSPCs (scale bars represent 5 mm) and in different cell lines as negative\low (–\lo) or positive (+)
controls (scale bars represent 10 mm).
± and error bars shown are the SD for the number of experiments performed. In immunocytochemistry stainings, cells were counterstained with DAPI and/or
rhodamine phalloidin (Rh-Pha.). In each experiment, 10–15 fields were captured. See also Figure S2.
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it to be a vehicle for the overexpression of ligands of interest.
We sorted //+ cells and cultured them for 5 days on S17
alone or S17 expressing Dll1, Dll4, or Jag1. There was an in-
crease inHES1 expression after coculture with each of the Notch
ligands, and markedly so for Dll4 (Figure 4A), demonstrating that
//+ cells respond to these ligands. We then analyzed
apoptosis, cell-cycle progression, expression of CD34, and abil-
ity to form colony-forming units (cfu) following coculture. No dif-
ferences in apoptosis by AnnexinV (Figure S3D) or upregulation
of proapoptotic genes (Figure S3E) were observed between the
different conditions. We observed that Dll1 had no effect on the
regulation of CD34 expression, cfu formation, and cell-cycle pro-
gression of //+ cells (Figures S3B and S3C). Because we did
not observe any effect of Dll1 on this immature population, at
least on the parameters studied, or detect Dll1 expression in
the placenta (Figure S3A), we did not pursue further analysis of
this ligand. Instead, we performed a more in-depth study of the
effects of the other two ligands, given that in preliminarily exper-
iments we observed that Dll4 and Jag1 appeared to specifically164 Cell Stem Cell 13, 161–174, August 1, 2013 ª2013 The Authorsregulate differentiation and cell-cycle progression, respectively,
of //+ cells (Figure S3F). Indeed, in addition to decreasing
CD34 expression (Figure 4B), coculture of //+ cells on S17-
Dll4 decreased primary cfus >2-fold without significantly altering
the type of colonies generated (Figure 4C). However, in second-
ary cfu assays, cells that were cultured on S17-Dll4 increased
cfus by 10-fold (Figure 4C), suggesting a similar latency in dif-
ferentiation as seen in the in vivo experiments.
In the presence of Dll4, many transcription factors in the
cultured cells were maintained at the same level as uncultured
//+ cells compared to those cultured on S17 alone, including
GATA2, LMO2, and TAL1 (Figure 4D). With respect to Jag1, a
greater proportion of cells cocultured on S17-Jag1 were main-
tained in G0 compared to those cultured on S17 alone (Fig-
ure 4E). Expression analysis indicated that many G0-G1 transi-
tion regulators were maintained in S17-Jag1 cocultured cells at
a similar level as uncultured cells (Figure 4F).
Genes commonly regulated through contact with either Jag1
or Dll4, such as SPI1 (PU.1), MPO, and p21CIP1 (presumably
acting through the common RBPJ-k-Hes1 axis) could have
Figure 3. Notch Signaling in Lin–CD34–CD38–CD93hi HSCs
(A) Extracellular Notch receptor expression. MFI ratio values (Notch receptors/isotype controls [Iso. Ctrl.]) are shown. Molt4, Raji, and B-CLL cells were used as
positive control for Notch1, Notch2, and Notch4 expression, respectively (n = 4).
(B) qRT-PCR for the expression of different components of the Notch pathway. //+ population was used as reference (n = 3–5).
(C) Intracellular flow-cytometry (FCM) analysis for Hes1 expression. Jurkat cell line was used as a positive control (n = 4).
(D) Detection of cleaved Notch1 (N1-IC cleav.), cleaved Notch2 (N2-IC cleav.), and N4-IC in the denoted CB populations, and different cell lines were used as
controls (n = 3, each with 10–15 fields captured). Scale bars represent 5 mm.
(E) Double-fluorescent immunostaining for Jag1, and Dll4, and aSMA or CD31 on paraffin sections of human placenta beds and umbilical cords (scale bars
represent 100 mm). Tissues were counterstained with DAPI.
Error bars represent SD. See also Figure S3.
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However, we observed thatmany of the changes in gene expres-
sion after coculture on S17-Jag1 or S17-Dll4 were mutually
exclusive (Figures 4D and 4F), without changes in HES5 and
HEY1 expression (data not shown). Also, DTX1 expression was
maintained in //+ cells when interacting only with Dll4 (Fig-
ure S3G). Notably, the addition of the g-secretase inhibitor
DAPT to the S17 cocultures resulted in the abrogation of the ef-
fects of Jag1 and Dll4, confirming that the effects seen acted
through the canonical Notch pathway (Figure S3F).
As reported above, following //+ cell transplantation, a
period of latency is observed, and with this in mind we hypothe-
sized that these immature HSCs could be receiving Notch sig-
nals from themouse BM.We first confirmed that the same Notch
receptors continue to be expressed on the //+ cells recov-
ered after primary transplantation with CB //+ HSCs, in
particular the Notch4 receptor (Figure 4G). The expression level
of Hes1 was also similar to that seen in CB //+ cells (Fig-Cure 4H). To examine its role, we temporarily blocked the Notch
pathway in vivo before the cells began differentiating (at 5 weeks
posttransplant) by administering DAPT, either 4 times (43) or 8
times (83), to mice transplanted with //+ cells. We observed
an 5-fold increase in engraftment with 43 DAPT compared to
controls, and 83 DAPT resulted in an additional increase in
engraftment (14-fold total; Figure 4I). However, this increase
in engraftment appears to be at the expense of the CD34+
compartment (Figure 4J). This observation is further supported
by the limited cfu capacity of the human cells isolated from
mice treated 83 (Figure 4K). Without the known toxicity of
DAPT treatment, we could expect an abrogation of the engraft-
ment if a continuous DAPT treatment was performed.
To better understand any differential role of the Notch pathway
between the //+ and +/ cells, we performed similar experi-
ments with the four +/ subfractions. We first observed that the
90+49f+ population, despite having a lower primary cfu capacity,
had better replating capacity compared to other subfractionsell Stem Cell 13, 161–174, August 1, 2013 ª2013 The Authors 165
Figure 4. Primitive and Quiescent Features of Lin–CD34–CD38–CD93hi HSCs Maintained by Notch Signaling
(A)HES1 expression in//+ cells that have been cultured for 5 days on S17 cells expressing the indicated ligand. Cells cultured on S17were used as a reference
(n = 3).
(B) CD34 expression on noncultured (NC) //+ and 5-day-cultured cells on S17 cells expressing the indicated ligand (n = 5). Representative FCM plot can be
seen in Figure S3F.
(C) Primary and secondary cfu assays evaluated with //+ and 5-day-cultured cells on S17 or S17-Dll4 stromal cell lines (n = 3, each in triplicate).
(D) qRT-PCR for the expression of different differentiation and ‘‘HSC fingerprint’’ genes as shown in (A). NC //+ cells were used as a reference population
(n = 3–5).
(E) Cell-cycle analysis of NC //+ and 5-day-cultured cells on S17 cells expressing the indicated ligand (n = 3–5).
(F) Expression of different cell-cycle regulator genes as in (A). NC //+ cells were used as a reference population (n = 3–5).
(G) Representative FCM histograms for Notch receptor expression on human//+ cells in primary NSG recipients’ BMs that were transplanted with5,000 CB
//+ cells 4–6 wks earlier. MFI ratio values are shown (n = 2, each with pool of 2–3 BMs).
(legend continued on next page)
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level of engraftment when transplantedwith a limited cell dose as
compared to others (Figure S4B). Altogether, this supports the
report that this population is highly enriched with HSCs (Notta
et al., 2011).
Upon culture with different Notch ligands, each subfraction re-
sponded differently to the different ligands (data not shown)
despite a comparable upregulation of HES1 in the different sub-
populations (Figure 4L). We focused on the impact of Dll4 given
that it had the strongest effect in repressing primary cfu formation
while enhancing the replating potential of the cells as compared
to cultures on S17 alone, specifically on the two CD90+ popula-
tions (data not shown, Figure 4M). Indeed, coculture on S17-
Dll4 repressed CEBPA, MPO, and GATA1 expressions in these
subpopulations (Figure S3H) as compared to the control condi-
tion. In contrast, interaction with Dll4 induced a substantial upre-
gulation of GATA1 expression in the two CD90 subpopulations
that resulted in an enhanced burst-forming unit erythroid (BFU-E)
formation compared to cultures with S17 alone (Figure 4M). In
analyzing cell-cycle regulation, we observed an increase in
p21CIP1 expression that resulted in an increase in G1 in all sub-
populations cultured on S17-Jag1 (Figures 4N and S3I).
We then went on to investigate whether this pathway is impor-
tant for the maintenance of +/ HSPCs in vivo as we observed
for the//+ population. We confirmed that the Notch receptors
were expressed on the +/ subfractions in the BM recovered
from primary recipients (Figure 4O). We also observed that
Hes1 is similarly expressed in the four fractions, albeit at a lower
level than in CB cells (Figures 3C and 4P). However, when we
temporarily blocked the Notch pathway by administering DAPT
43 or 83 to mice transplanted with +/ HSPCs, we observed
an 50% reduction in engraftment only when mice were treated
83 as compared to control (Figure 4Q). Furthermore, the 83
treatment reduced the +/ compartment (Figure 4R) by affecting
all the +/ subfractions equally (Figure S3J). Altogether, these
results suggest that although both //+ and +/ populations
can respond efficiently to Notch signals in vitro, albeit differently;
the Notch pathway plays a larger role in controlling the differen-
tiation of//+ cells to +/HSPCs than the latter to subsequent
progenitors (e.g., CD34+CD38+) in vivo.(H) Immunocytochemistry of Hes1 in NC CB//+ cells and a phenotypically sim
5–10 fields captured. Scale bars represent 5 mm.
(I) 5,000 CB //+ cells were transplanted into NSG mice. Five weeks later, mic
were analyzed at 12 weeks. Median bars are shown.
(J) Frequency of human LinCD34+CD38/lo or LinCD34+ populations generated
cells as described in (I).
(K) cfu assay with human cells sorted from mice as described in (I), n = 5.
(L) HES1 expression in different +/ subpopulations after 5 days of culture on diff
used as a reference population (n = 3–5).
(M) Primary (left) and secondary (right) cfu colonies assayed with +/ subpopul
duplicate).
(N) Cell-cycle analysis of different +/ subpopulations after 5 days of culture on
(O) Extracellular Notch receptor expression on different engrafted +/ subpop
750 CB +/ HSPCs (n = 5).
(P) FCM analysis for Hes1 expression in different engrafted +/ subpopulations
(Q) 750 CB+/ cells were transplanted into NSGmice and 5weeks later were trea
Median bars are shown.
(R) Frequency of human LinCD34+CD38/lo populations generated in mice treate
in (Q).
Error bars represent SD; *p% 0.03, **p% 0.003, ***p% 0.0003. See also Figure
CTGF-b Signaling Also Participates in the Maintenance of
the Quiescent State of Lin–CD34–CD38–CD93hi HSCs
During our analyses, we observed that the expression of p57KIP2
(CDKN1C) is the most abundant cyclin-dependent-kinase (CDK)
inhibitor in//+ cells, and its expression was reduced following
coculture of //+ cells with S17 but remained higher than that
of p21CIP1 in uncultured primary //+ cells (data not shown).
Given that p57KIP2 is a known target of TGF-b signaling and
that TGF-b1 is highly expressed in the placenta villi (but only
slightly in the mesenchyme surrounding the umbilical cord ar-
teries and vein) (Figure 5A), we wanted to evaluate whether this
pathway might also contribute to the cell-cycle status of //+
cells.
First, we confirmed that //+ cells express high levels of the
TGF-b receptors (TGF-bRs), downstream effector genes,
TGFb1, and some of its activators via quantitative RT-PCR
(qRT-PCR) (Figure 5B). We further confirmed the expression of
TGRbRII (Figure S5A), the nuclear localization of Foxo3a (Fig-
ure S5B), and the phosphorylation of Smad-3 (p-Smad3) (Fig-
ure S5C). The expression of these components of TGF-b
signaling suggests that these cells are capable of receiving
TGF-b signals efficiently from the placenta villi. We therefore first
tested the response of these cells with TGF-b in vitro by culturing
//+ cells with TGF-b1 and observed an upregulation of
p-Smad3 (Figure S5C). Using the S17 coculture system we
pulsed the //+ cells with low doses of TGF-b1 (2.5 ng/ml)
and/or a function-blocking antibody twice over the course of
5 days. We observed that TGF-b1 was able to block cell-cycle
progression (Figure 5C) and found that expression of p57KIP2
and E2F1was brought back to levels similar to those seen in un-
cultured//+cells (Figure5D), aneffect notobservedwithJag1.
Second, we wished to evaluate the importance of the TGF-b
pathway in //+ cells in vivo. Following primary transplanta-
tion, the levels of p-Smad3 remain upregulated in the engrafted
//+ population (Figure 5E), and we hypothesized that tempo-
rarily blocking the TGF-b pathway would cause the //+ cells
to exit G0 and result in better engraftment levels. To test this,
we injected mice with 43 or 83 SB431542, a TGF-bR inhibitor,
5 weeks after they were transplanted with //+ cells. We
observed an 7-fold increase in the engraftment levels of miceilar population found in primary NSG recipients’ BMs as in (G). n = 2, each with
e were treated with vehicle or 43 or 83 with DAPT. Mice were killed and BMs
in mice treated with vehicle or 43 or 83 with DAPT engrafted with CB //+
erent ligand-expressing S17 cells. The 90+49f+ population cultured on S17 was
ations after 5 days of culture on S17 or S17-Dll4 stromal cells (n = 5, each in
S17 or S17-Jag1 stromal cells (n = 3).
ulations in primary NSG recipients’ BMs at 4–6 weeks posttransplant with
as in (O) (n = 5).
tedwith vehicle or 43 or 83with DAPT. Engraftment was analyzed at 12weeks.
d with vehicle or 43 or 83with DAPT engrafted with CB +/ cells as described
S4.
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Figure 5. Quiescent Nature of Lin–CD34–CD38–CD93hi HSCs through the TGF-b/p57kip2 Axis
(A) Double-fluorescent immunostaining for TGF-b1 and aSMA or CD31 on paraffin sections of human placenta bed and umbilical cords (scale bars represent
100 mm).
(B) Expression of different components of the TGF-b pathway in the different CB HSPC populations by qRT-PCR. //+ cells were used as the reference
(n = 3–5).
(C) Cell-cycle analysis of NC //+ cells and 5-day-cultured cells on S17 stromal alone or with two pulses of TGF-b1 (2.5 ng/ml) or TGF-b1+TGF-b1-blocking
antibody (n = 4).
(D) qRT-PCR for different cell-cycle regulator genes as in (C). NC //+ cells were used as the reference population (n = 3–5).
(E) Representative FCMhistogram of p-Smad3 expression in engrafted//+ cells in primary recipients’ BM transplanted with5,000 CB//+ cells 4–6weeks
earlier. MFI ratio is shown (n = 2, each with a pool of 2–3 BMs).
(F) Approximately 5,000 CB //+ cells were transplanted into each NGS mouse. Five weeks later, mice were treated either with vehicle or 43 or 83 with
SB431542. Engraftment was analyzed at 12 weeks. Median bars are shown.
(G) p-Smad3 expression in CB +/ HSPCs and different LinCD34+CD38CD45RACD90+orCD49f+or fractions (n = 4).
(H) Cell-cycle analysis of +/ subfractions cultured for 5 days on S17 stroma alone or with two pulses of TGF-b1 (2.5 ng/ml) or TGF-b1+TGF-b1-blocking antibody
(n = 3).
(I) 750 CB+/ cells were transplanted into NSGmice, and 5weeks latermicewere treatedwith vehicle or 43 or 83xwith SB431542. Engraftment was analyzed at
12 weeks. Median bars are shown.
(J) p-Smad3 expression in different human +/ subpopulations in primary NSG recipients’ BMs at 4–6 weeks posttransplantation with CB 750 +/ HSPCs. MFI
ratio values are shown (n = 5).
± and error bars shown represent SD; *p% 0.03, **p% 0.003. See also Figure S5.
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83, engraftment was almost abrogated (Figure 5F), suggesting
that the TGF-b pathway is strongly involved in the maintenance
of//+ cells in a quiescent state in vivo. Unlike the DAPT treat-
ment, the frequency of +/ cells generated from//+ cells after
SB431542 treatment was the same as for controls (data not
shown), suggesting that the cell-cycle progression of//+ cells
is not necessarily coupled with differentiation.
Again, to understand the relationship between the//+ pop-
ulation and the +/ HSPCs, we looked at TGF-b signaling in the168 Cell Stem Cell 13, 161–174, August 1, 2013 ª2013 The Authorsfour +/ subfractions. First, we observed that p-Smad3was pre-
sent (Figure 5G) and all the fractions were able to respond
equally to TGF-b1 in the S17 coculture system, demonstrated
through a decrease in cycling cells (Figure 5H). However, when
we temporarily blocked the TGF-b pathway in vivo by adminis-
tering SB431542, we observed no effect on the level of engraft-
ment, even after 83 (Figure 5I). Additionally, we observed a low
level of p-Smad3 expression, which is indicative of low TGF-b
signaling, in all the engrafted +/ subfractions (Figure 5J). These
observations are in contrast to those seen in the//+ cells and
Figure 6. Repressed Canonical Wnt Pathway in Lin–CD34–CD38–CD93hi HSCs
(A) FCMstaining for total b-catenin expression of in the stated CBHSPC subpopulations. Noncultured, NC; stimulatedwithWnt3A alone, +; or in combinationwith
LiCl, ++; for 8 hr (n = 6).
(B) qRT-PCR for the expression of components of the canonical Wnt pathway in the different CB HSPC populations. +/ cells were used as the reference (n = 4).
(C) Primary cfu colonies generated from noncultured (NC); cultured (C); or nucleofected then cultured without any plasmid (Nu.+C), with the construct over-
expressing DLEF1, or with the control vector (pcDNA3) +/ cells.
(D) Secondary colonies derived from +/ HSPCs that were subjected to different conditions as described in (C).
(E) Expression of a selected group of genes in +/ HSPCs that have been treated as in (C). Cultured cells were used as the reference (n = 3).
(F) Expression of different LEF1 isoforms in NC//+ cells and after culturing in different S17 stromal cell lines for 5 days. Cells cultured on S17 were used as the
reference (n = 3).
Error bars shown represent SD; *p% 0.03. See also Figure S6.
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maintenance of the quiescent state of //+ cells as compared
to +/ HSPCs in vivo, at least in the context of xenograft
environments.
Lin–CD34–CD38–CD93hi HSCs Have a Repressed
Canonical Wnt Pathway
Our observations indicated that//+ cells are refractory to sig-
nals that induce proliferation. We therefore decided to investi-
gate the canonical Wnt pathway, given that it has been shown
to drive HSC proliferation both in vitro and in vivo (Kirstetter
et al., 2006; Scheller et al., 2006).
Using a T cell factor/lymphoid-enhancing factor (TCF/LEF) re-
porter assay, we detected an absence of basal canonical Wnt
activity in the //+ population as compared to the +/ HSPCs
(Figure S6A). Additionally, we observed a weak stabilization and
accumulation of b-catenin when stimulated with canonical
Wnt3A compared to all other +/ fractions (Figure 6A). Further
activation of the pathway through inhibition of GSK3b by LiCl
(Figure 6A) did not alter the outcome, indicating that the //+
population did not have a higher level of b-catenin proteasomal
degradation compared to the other populations. These resultsCsuggest that these immature cells haveminimalWnt pathway ac-
tivity and are resistant to canonical Wnt ligands. Looking at the
expression of the different receptors, we could not find any sub-
stantial differences that could account for the differentWnt activ-
ity seen in the different hematopoietic populations (Figure S6B).
An alternative explanation could lie downstream of the recep-
tors. Indeed, we observed higher levels of expression of AXIN1
andCSNK1A1 and lower levels of TCF7L2 expression (Figure 6B)
(at the protein level also, Figure S6C), confirming low levels of
canonical Wnt signaling in //+ cells compared to the other
CD34+ populations. Interestingly, we found high levels of LEF1,
but this was limited to the short splicing variant form, which lacks
the b-catenin binding domain (SF-LEF1, Figure 6B). This Lef1
isoform has been demonstrated to function as a repressor for
the same genes that the long-form Lef1/b-catenin complex acti-
vates (Hovanes, et al., 2001). As such, wewonderedwhether this
short form of Lef1 had any functional significance. Again, given
that it is difficult to manipulate //+ cells for any significant
period of time in vitro, we were not able to overexpress the
long form of Lef1 (LF-Lef1) to compete with the endogenous
SF-Lef1 that is more abundant in this population. As an alterna-
tive approach, we transiently overexpressedDLef1 (a formwith aell Stem Cell 13, 161–174, August 1, 2013 ª2013 The Authors 169
Figure 7. Cellular and Molecular Features of BM Lin–CD34–CD38–CD93hi Cells
(A) Frequency of//+ cells and different +/ subpopulations found in CB (left), GMPB (middle), and BM (right), n = 5–7. Representative FCMplots of this analysis
are shown in Figure S7.
(B) Cell-cycle profile of human adult BM //+ and +/ populations determined by Ki67 and DAPI staining (n = 3).
(C) qRT-PCR for different cell-cycle regulator genes. The //+ population was used as the reference population (n = 3).
(legend continued on next page)
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SF-Lef1) in +/ HSPCs to see whether an abundance of this
variant would compete with the long form and repress canonical
Wnt or other non-Wnt target genes. We nucleofected +/
HSPCs with the DLEF1 expression vector and subsequently
cultured them for 3 days with cytokines known to promote differ-
entiation. When overexpressing DLEF1, the capacity of the cells
to form primary colonies was reduced compared to the controls
to numbers similar to the cultured, nonnucleofected condition
(Figure 6C). However, in replating assays, the numbers of sec-
ondary colonies were increased compared to controls (Fig-
ure 6D). From this it appears that the DLEF1 variant was able
to suppress their differentiation and increase replating capacity.
Additionally, we analyzed these cells by qRT-PCR for genes
affected by the nucleofection with DLEF1. Of the panel of genes
analyzed, CEBPA, TCF7L2, and CTNNB1 (b-catenin) were
downregulated in the DLEF1 nucleofected cells as compared
to the control vector (Figure 6E). CEBPA is not a canonical Wnt
target gene, given that expression was not increased following
stimulation with Wnt3A in vitro, in contrast to target genes
such as TCF7L2, CTNNB1, and CCND1 (Figure S6D).
To investigate whether this reduction in CEBPA was linked to
that observed following coculturing of //+ cells with Dll4 (Fig-
ure 4D), we analyzed SF-LEF1 expression following exposure to
Dll4. Interestingly, we observed that//+ cells maintained their
SF-LEF1 levels upon treatment with Dll4 (Figure 6F), suggesting
that Dll4 acts on //+ cells by blocking differentiation partly
through the regulation of SF-LEF1 expression.
The Lin–CD34–CD38–CD93hi Population Exists in Human
BM and Has Similar Features to Its CB Counterpart
It has been demonstrated that human BM LinCD34 cells can
engraft a preimmune sheep model (Zanjani et al., 1998), BM
LinCD34CD38 cells can engraft NOD/SCID mice (Bhatia
et al., 1998), and human granulocyte colony-stimulating factor-
mobilized peripheral blood (GMPB) LinCD34 cells can repo-
pulate NOD/SCID mice (Lemoli et al., 2003). With this in mind,
we were interested to see whether a cell population phenotypi-
cally similar to the CB //+ cell population existed in human
adult hematopoietic tissues. Phenotypically, these cells can be
found in GMPB and BM samples, albeit at a 10-fold-lower fre-
quency (relative to CD34+ cells) compared to CB (Figure 7A).
We were able to identify a nonendothelial hematopoietic popula-
tion comprising 0.174% and 0.194% of BM and GMPB
CD34+ cells, respectively (Figures 7A, S7A, and S7B). Interest-
ingly, in BM, we showed that //+ cells were more quiescent
than +/ HSPCs (Figures 7B and 7C). We also observed
that these BM //+ cells had substantial cell-surface expres-(D) Extracellular Notch receptor expression by FCM. MFI ratio values (Notch rece
used as controls for the expression of the receptors (n = 3).
(E) Expression of different components of the Notch pathway in the denoted BM
(F) Hes1 expression in BM //+ and +/ populations. MFI values are shown (n
(G) Expression of TGF-b target genes in the denoted BM populations. The //+
(H) Expression of different components of the Wnt pathway in the denoted BM p
(I) Quantification of the basal canonical Wnt activity by TCF reporter assay in the
(J) Intracellular FCM analysis for TCF4 expression in the denoted BM population
(K) Graphic representation of the signaling pathways involved in the regulation of
(represented by ‘‘?’’) involved in the Notch signaling in //+ HSCs.
Error bars shown represent SD.
Csion of different Notch receptors (Figure 7D) and higher expres-
sion of the components of the Notch pathway and Hes1
expression compared to +/ HSPCs (Figures 7E and 7F).
Furthermore, similar to their CB counterparts, these quiescent
BM cells had a higher level of basal TGF-b signaling but low or
absent basal canonical Wnt activity (Figures 7G–7J). Collec-
tively, these data support the existence of a //+ cell popula-
tion in adult BM, which shares some of the cellular andmolecular
features of its CB counterpart.
DISCUSSION
The CD34 SRC was first described in 1998 by Dick and col-
leagues (Bhatia et al., 1998) and has subsequently been
confirmed in other studies (Danet et al., 2002; Wang et al.,
2003). Contrary to the report by Dao et al. (2003), our results
are consistent with previous observations that +/ HSPCs are
not able to give rise to a functionally equivalent / population
capable of producing secondary grafts in vivo when employing
the same primary and secondary recipient mouse model
(Wang et al., 2003), in that / cells derived from +/ HSPCs
are differentiated cells, such as macrophages, and not +/ cells
that have downregulated CD34 expression (Dao et al., 2003).
Building on this, we demonstrate the self-renewal capacity of
the CB CD34 SRC in the mouse model, which Wang et al.
(2003) failed to show, perhaps because of the lower number of
cells injected as compared to this study.
We show that //+ cells, when uncultured, have almost no
plating capacity and produce a delayed and low level of primary
engraftment at 12 weeks posttransplant. A close inspection of
published data shows that all of the +/ subfractions that have
been recently described can give rise to myelo-lymphoid repo-
pulation at 5 weeks (Notta et al., 2011). Throughout our study
of the //+ cells, we did not observe an enhanced level of
engraftment at early time points by injecting more cells or by
changing mouse models. We obtained quite similar levels of
engraftment in NOD/SCID-b2/ and NSG mice as in our previ-
ous report in NOD/SCID mice, reflecting comparable SRC fre-
quencies in different mouse models when using intravenous de-
livery: 1 in 75,000 / cells in NOD/SCID (D.B., unpublished
data), 1 in 62,500 / cells in NOD/SCID-b2/, and 1 in
7,500 //+ cells in NOD/SCID (Danet et al., 2002), compared
to 1 in 6,100 //+ cells in NSG (F.A.-A., unpublished data).
This differs from the well-documented repopulating behavior
of +/ HSPCs, wherein SRC frequency changes with the mouse
strain. Also, unlike +/ cells, where the SRC frequency can be
increased 15-fold when injected intrabone (Yahata et al.,
2003), we observed only a2-fold increase with / cells usingptors/isotype controls) are shown. Different cells lines and primary cells were
populations. The //+ population was used as the reference (n = 3).
= 3).
population was used as the reference (n = 3).
opulations. The +/ population was used as the reference (n = 3).
different BM populations (n = 3).
s (n = 3).
//+ HSCs described in this study. Hypothetical Notch ligand-receptor pairing
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engraftment level produced by //+ cells matched or sur-
passed the level generated by +/ HSPCs at 6 months post-
transplant. We suggest that interpretations should be made
with caution when comparing SRC frequencies between //+
and +/ cells (or with any of the subfractions) at a given time
point, because these populations have distinct engraftment ki-
netics. More importantly, the newly generated +/ cells from
CB CD34 cells have better secondary repopulation and replat-
ing capacities compared to those from CB +/ HSPCs.
Having identified the potential of this population, we wished to
characterize the cellular and molecular mechanisms that might
dictate its behavior. First, we demonstrate that //+ cells are
highly quiescent, a hallmark of stem cells. Furthermore, the
expression of important HSC developmental regulators, de-
noted here as an HSC fingerprint, suggests that the //+ pop-
ulation represents an immature cell type. Indeed, the molecular
features indicative of a quiescent and primitive cell state are re-
flected by the in vitro and in vivo behaviors observed.
We were therefore interested in dissecting the signaling path-
ways responsible for controlling the unique features of the//+
population. We found that the Notch pathway is not only active in
freshly isolated CB//+ cells but also plays an important role in
themaintenance of the immature and quiescent features of these
cells. We show that //+ cells demonstrate a unique Notch4
expression and cleavage pattern. Moreover, when these cells
interact with Dll4, but not with Dll1 or Jag1, the upregulation of
CD34 expression and induction of clonogenic activity are halted,
which is accompanied by the repression of HSC fingerprint tran-
scription factors. This, in combination with the high Dll4 expres-
sion found in their native environment, supports the idea that the
immature features of //+ cells are dictated, at least in part,
through this pathway.
Despite each of the +/ subfractions responding distinctively
in vitro to each of the ligands, our data suggest that +/ cells are
less dependent on Notch signals in vivo compared to //+
cells. When we temporarily blocked this pathway, //+
HSCs gave rise to more +/ HSPCs, resulting in a higher level
of engraftment in vivo; however, a prolonged inhibition led to
exhaustion of the system. This is in contrast to the effect
on +/ HSPCS, wherein the effects of Notch inhibition are
only seen after extended inhibition of this pathway. One of the
most interesting aspects of this study is that many of the
changes in gene expression in //+ cells and in different +/
subpopulations after coculture with different Notch ligands
appear to be exclusive. This suggests that the effects of Notch
signaling are context dependent and cell specific and that atten-
tion is therefore required when different cell populations are
compared.
With respect to cell-cycle regulation, it appears that the quies-
cent state of //+ cells is regulated, at least in part, by a com-
bination of Jag1 and TGF-b signaling. Our results suggest that
Notch signaling driven by Jag1 binding can sustain cells in G0
by blocking the G0-G1 transition, whereas TGF-b1 stimulation
can sustain p57KIP2 expression. Given that we saw considerable
TGF-b signaling in //+ cells, we believe that p57KIP2 might be
one of the key factors that prevent//+ cells from entering and
progressing through G1 phase. Furthermore, we have shown
that different +/ subfractions can respond efficiently to TGF-b172 Cell Stem Cell 13, 161–174, August 1, 2013 ª2013 The Authorssignals in vitro as previously shown for the bulk +/ population
(Scandura et al., 2004). Interestingly, only //+ cells seem to
have amore active TGF-b signaling pathway in vivo as compared
to any of the +/ subpopulations. As a result, engrafted //+
cells respond when this pathway is inhibited, whereas +/
HSPCs do not.
One of themost intriguing characteristics of//+ cells is their
unresponsive nature to external stimuli, something that has been
a major obstacle to their study both in vitro and in vivo. With
respect to this, we decided to focus on the canonical Wnt
pathway, one that might act to block differentiation. We demon-
strate first that//+ cells have an absent or low basal canonical
Wnt pathway and are refractory to canonical Wnt signals. Unex-
pectedly, we observed an exclusive expression of the short iso-
form of the transcription factor LEF1 in this quiescent and imma-
ture cell population. We were able to confirm the importance of
this variant of Lef1 by showing that it not only represses the
expression of TCF4 and CTNNB1, but also of CEBPA, which is
normally induced by hematopoietic cytokines. This suggests
that SF-Lef1 in //+ cells represses the expression of some
of the components of the canonical Wnt pathway, rendering
them unable to convey Wnt signals, alongside transcription fac-
tors induced by other stimuli. Remarkably, we also found that the
expression of SF-LEF1 seems to be regulated byNotch signaling
through Dll4. This finding provides additional support for the
importance of Dll4 interactions in //+ cells and suggests an
additional connection between the Notch pathway and (repres-
sive) canonical Wnt signaling in this immature and quiescent
population.
We attempted to further subfractionate this //+ population
with antigens recently used to subfractionate the +/ HSPC
population, hoping to find a potential developmental link with
the +/ compartment. Although phenotypically these immature
//+ HSCs differ from the 90+49f+ subfraction, both popula-
tions appear to share some biological features. For example,
in vitro replating potential, response to Dll4 signals, and in vivo
self-renewal capacity are similar between these two populations
as compared with the remaining +/ subfractions (Notta et al.,
2011). However, none of the +/ subpopulations, including the
90+49f+ HSCs, have the degree of dormancy and immaturity
that the //+ HSCs have, as seen through their different
engraftment kinetics, SRC frequencies, and response to prolifer-
ative signals. These and other results strongly suggest that the
CD34 SRC represents a distinctive class of human HSCs (Bha-
tia et al., 1998; Danet et al., 2002; Wang et al., 2003). We would
also like to emphasize that antigens that are currently used to
subfractionate the +/ population are not of any use in further
subdividing the //+ cells, and interpretation of comparative
studies between such different cell types should be performed
with caution.
Finally, we uncovered only small differences between the
four +/ subfractions in terms of their molecular signatures
and signaling pathways at the basal level. These findings were
not totally surprising, given that published microarray data did
not reveal differences between the subfractions for the signaling
pathways illustrated here (Notta et al., 2011).
Taking these results together, we provide an extensive cellular
and molecular characterization of //+ cells (Figure 7L). The
data strongly supports the idea that the //+ population
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matopoietic hierarchy above +/ HSPCs. Given the existence
of these CD34 cells in human adult hematopoietic tissues (Bha-
tia et al., 1998; Lemoli et al., 2003; Zanjani et al., 1998), we pro-
pose that these //+ HSCs could represent the human
equivalent of the mouse a-CD45midlinRhoSP and/or the
CD34KLSCD150hi HSCs (Dykstra et al., 2007; Morita et al.,
2010) based on their similar in vivo engraftment behavior of
delayed primary and efficient secondary engraftment.
This work provides the foundation for future research into the
hierarchy of human HSCs and the developmental relationship of
these cells with +/ long-term HSCs. Importantly, the character-
ization of the CD34 compartment provides the implication for
both scientific and clinical communities that these cells might
be of importance for human cell therapy.
EXPERIMENTAL PROCEDURES
Primary Cells
CB was obtained after informed consent at St Bartholomew’s and the Royal
London Hospitals. The protocol was approved by the East London Ethical
Committee. Two or more CB samples were pooled for each experiment, and
mononuclear cells (MNCs) were obtained by density centrifugation using
Ficoll-Paque (GEHealthcare Life Sciences). Mature cells were removed via im-
munomagnetic depletion using StemSep Human Hematopoietic Progenitor
Cell Enrichment Cocktail (STEMCELL Technologies) according to the manu-
facturer’s protocol. In some experiments, MNCs depleted of CD34+ cells
with the EasySep Human CD34 Positive Selection Kit were used to isolate line-
age-negative CD34 cells. Cells lacking lineage markers (Lin) were used for
all intracellular immunostaining for determining the activity of the signaling
pathways and were obtained as fast as possible, with all the procedures per-
formed cold (including staining, cell washing, and cell collection during deple-
tion) and carried out with PBS containing 2%CB serum in order to preserve as
much as possible the natural activity of the pathways. Human BMMNCs were
purchased from Lonza Biologics, and Lin cells were obtained as described
for CB MNCs.
Immunophenotyping
Cells were incubated with antibodies (see Table S1) for 30 min at 4C in PBS/
2% fetal bovine serum, washed, and resuspended in DAPI-containing solution
before analysis on an LSR II flow cytometer (BD Biosciences). When unconju-
gated or biotin-conjugated primary antibodies were used, the appropriate sec-
ondary antibody or streptavidin binding step was used, respectively, with
washes performed between incubations. For all multicolor analysis, Fluores-
cence Minus One controls—wherein all other specific staining is in the same
tube minus the one of interest, which is replaced with an appropriate iso-
type-matched control—were included for determining the fluorescence
thresholds. Gates were set up to exclude nonviable cells and debris during
analysis.
Please refer to Supplemental Experimental Procedures for the remaining
methodologies, materials, and reagents used for the preparation of this
manuscript.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2013.05.025.
ACKNOWLEDGMENTS
This work was funded by Cancer Research UK (to D.B.). Authors are grateful to
the staff at the Biological Resources Unit and Flow Cytometry core facilities for
their valuable technical help. We would like to thank Dr. Stuart Horswell for his
valuable help with the statistical analysis and Dr. Elena Siapati for her valuableCcomments. We are thankful to Drs. Evelyne Lauret (Cochin University Hospital,
Paris, France) and Anne-Marie Buckle (Univeristy of Manchester, Manchester,
UK) for providing different S17 stroma cell lines. F.A.-A. designed and per-
formed all experiments, analyzed data, and wrote the manuscript. E.C. helped
perform experiments and wrote the manuscript. K.E.F. and D.C.T. helped
perform experiments; H.G.P. helped design experiments and provided re-
agents. D.B. supervised the project, provided resources, and edited the
manuscript.
Received: March 8, 2012
Revised: April 4, 2013
Accepted: May 29, 2013
Published: August 1, 2013REFERENCES
Bhatia, M., Bonnet, D., Murdoch, B., Gan, O.I., and Dick, J.E. (1998). A newly
discovered class of human hematopoietic cells with SCID-repopulating activ-
ity. Nat. Med. 4, 1038–1045.
Danet, G.H., Luongo, J.L., Butler, G., Lu, M.M., Tenner, A.J., Simon, M.C., and
Bonnet, D.A. (2002). C1qRpdefines a new human stem cell population with he-
matopoietic and hepatic potential. Proc. Natl. Acad. Sci. USA 99, 10441–
10445.
Dao, M.A., Arevalo, J., and Nolta, J.A. (2003). Reversibility of CD34 expression
on human hematopoietic stem cells that retain the capacity for secondary
reconstitution. Blood 101, 112–118.
Delaney, C., Varnum-Finney, B., Aoyama, K., Brashem-Stein, C., and
Bernstein, I.D. (2005). Dose-dependent effects of the Notch ligand Delta1 on
ex vivo differentiation and in vivo marrow repopulating ability of cord blood
cells. Blood 106, 2693–2699.
Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., Lee,
S.J., Brinkman, R., and Eaves, C. (2007). Long-term propagation of distinct he-
matopoietic differentiation programs in vivo. Cell Stem Cell 1, 218–229.
Fryer, C.J., White, J.B., and Jones, K.A. (2004). Mastermind recruits
CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with
turnover. Mol. Cell 16, 509–520.
Goodell, M.A., Rosenzweig,M., Kim, H., Marks, D.F., DeMaria, M., Paradis, G.,
Grupp, S.A., Sieff, C.A., Mulligan, R.C., and Johnson, R.P. (1997). Dye efflux
studies suggest that hematopoietic stem cells expressing low or undetectable
levels of CD34 antigen exist in multiple species. Nat. Med. 3, 1337–1345.
Hovanes, K., Li, T.W., Munguia, J.E., Truong, T., Milovanovic, T., Lawrence
Marsh, J., Holcombe, R.F., andWaterman, M.L. (2001). Beta-catenin-sensitive
isoforms of lymphoid enhancer factor-1 are selectively expressed in colon
cancer. Nat. Genet. 28, 53–57.
Ilagan, M.X., Lim, S., Fulbright, M., Piwnica-Worms, D., and Kopan, R. (2011).
Real-time imaging of notch activation with a luciferase complementation-
based reporter. Sci. Signal. 4, rs7.
Kirstetter, P., Anderson, K., Porse, B.T., Jacobsen, S.E., and Nerlov, C. (2006).
Activation of the canonical Wnt pathway leads to loss of hematopoietic stem
cell repopulation and multilineage differentiation block. Nat. Immunol. 7,
1048–1056.
Kuc¸i, S., Wessels, J.T., Bu¨hring, H.J., Schilbach, K., Schumm, M., Seitz, G.,
Lo¨ffler, J., Bader, P., Schlegel, P.G., Niethammer, D., and Handgretinger, R.
(2003). Identification of a novel class of human adherent CD34- stem cells
that give rise to SCID-repopulating cells. Blood 101, 869–876.
Lauret, E., Catelain, C., Titeux, M., Poirault, S., Dando, J.S., Dorsch, M.,
Villeval, J.L., Groseil, A., Vainchenker, W., Sainteny, F., and Bennaceur-
Griscelli, A. (2004). Membrane-bound delta-4 notch ligand reduces the prolif-
erative activity of primitive human hematopoietic CD34+CD38low cells while
maintaining their LTC-IC potential. Leukemia 18, 788–797.
Lemoli, R.M., Bertolini, F., Petrucci, M.T., Gregorj, C., Ricciardi, M.R., Fogli,
M., Curti, A., Rabascio, C., Pandolfi, S., Ferrari, S., et al. (2003). Functional
and kinetic characterization of granulocyte colony-stimulating factor-primed
CD34- human stem cells. Br. J. Haematol. 123, 720–729.ell Stem Cell 13, 161–174, August 1, 2013 ª2013 The Authors 173
Cell Stem Cell
Characterization of Human CD34 HSCsMorita, Y., Ema, H., and Nakauchi, H. (2010). Heterogeneity and hierarchy
within the most primitive hematopoietic stem cell compartment. J. Exp.
Med. 207, 1173–1182.
Nakamura, Y., Ando, K., Chargui, J., Kawada, H., Sato, T., Tsuji, T., Hotta, T.,
and Kato, S. (1999). Ex vivo generation of CD34(+) cells from CD34(-) hemato-
poietic cells. Blood 94, 4053–4059.
Notta, F., Doulatov, S., Laurenti, E., Poeppl, A., Jurisica, I., and Dick, J.E.
(2011). Isolation of single human hematopoietic stem cells capable of long-
term multilineage engraftment. Science 333, 218–221.
Scandura, J.M., Boccuni, P., Massague´, J., and Nimer, S.D. (2004).
Transforming growth factor beta-induced cell cycle arrest of human hemato-
poietic cells requires p57KIP2 up-regulation. Proc. Natl. Acad. Sci. USA 101,
15231–15236.
Scheller, M., Huelsken, J., Rosenbauer, F., Taketo, M.M., Birchmeier, W.,
Tenen, D.G., and Leutz, A. (2006). Hematopoietic stem cell and multilineage
defects generated by constitutive beta-catenin activation. Nat. Immunol. 7,
1037–1047.174 Cell Stem Cell 13, 161–174, August 1, 2013 ª2013 The AuthorsStorms, R.W., Goodell, M.A., Fisher, A., Mulligan, R.C., and Smith, C. (2000).
Hoechst dye efflux reveals a novel CD7(+)CD34(-) lymphoid progenitor in hu-
man umbilical cord blood. Blood 96, 2125–2133.
Wang, J., Kimura, T., Asada, R., Harada, S., Yokota, S., Kawamoto, Y.,
Fujimura, Y., Tsuji, T., Ikehara, S., and Sonoda, Y. (2003). SCID-repopulating
cell activity of human cord blood-derived CD34- cells assured by intra-bone
marrow injection. Blood 101, 2924–2931.
Yahata, T., Ando, K., Sato, T., Miyatake, H., Nakamura, Y., Muguruma, Y.,
Kato, S., and Hotta, T. (2003). A highly sensitive strategy for SCID-repopulating
cell assay by direct injection of primitive human hematopoietic cells into NOD/
SCID mice bone marrow. Blood 101, 2905–2913.
Zanjani, E.D., Almeida-Porada, G., Livingston, A.G., Flake, A.W., and Ogawa,
M. (1998). Human bone marrow CD34- cells engraft in vivo and undergo multi-
lineage expression that includes giving rise to CD34+ cells. Exp. Hematol. 26,
353–360.
